Ferriprox 1000mg tablets

País: Reino Unido

Idioma: inglés

Fuente: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredientes activos:

Deferiprone

Disponible desde:

Swedish Orphan Biovitrum Ltd

Código ATC:

V03AC02

Designación común internacional (DCI):

Deferiprone

Dosis:

1gram

formulario farmacéutico:

Tablet

Vía de administración:

Oral

clase:

No Controlled Drug Status

tipo de receta:

Valid as a prescribable product

Resumen del producto:

BNF: ; GTIN: 0771313210850

Información para el usuario

1
PACKAGE LEAFLET: INFORMATION FOR THE USER
FERRIPROX 1000 MG FILM-COATED TABLETS
Deferiprone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
−
Keep this leaflet. You may need to read it again.
−
If you have any further questions, ask your doctor or pharmacist.
−
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
−
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
−
Attached to this leaflet you will find a patient/carer reminder card.
You should detach, complete,
read the card carefully and carry it with you.
WHAT IS IN THIS LEAFLET:
1.
What Ferriprox is and what it is used for
2.
What you need to know before you take Ferriprox
3.
How to take Ferriprox
4.
Possible side effects
5.
How to store Ferriprox
6.
Contents of the pack and other information
1.
WHAT FERRIPROX IS AND WHAT IT IS USED FOR
Ferriprox contains the active substance deferiprone. Ferriprox is a
medicine that removes iron from the
body.
Ferriprox is used to treat iron overload caused by frequent blood
transfusions in patients with
thalassaemia major when current chelation therapy is contraindicated
or inadequate.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE FERRIPROX
DO NOT TAKE FERRIPROX
−
if you are allergic to deferiprone or any of the other ingredients of
this medicine (listed in
section 6).
−
if you have a history of repeated episodes of neutropenia (low white
blood cell (neutrophil)
count).
−
if you have a history of agranulocytosis (very low white blood cell
(neutrophil) count).
−
if you are currently taking medicines known to cause neutropenia or
agranulocytosis (see “Other
medicines and Ferriprox”).
−
if you are pregnant or breast-feeding.
WARNINGS AND PRECAUTIONS
−
the most serious side effect that may occur while taking Ferriprox is
a very low white bl

Ficha técnica

OBJECT 1
FERRIPROX 500 MG FILM-COATED TABLETS
Summary of Product Characteristics Updated 09-Aug-2017 | Swedish
Orphan Biovitrum Ltd
1. Name of the medicinal product
Ferriprox 500 mg film-coated tablets
Ferriprox 1000 mg film-coated tablets
2. Qualitative and quantitative composition
Ferriprox 500 mg film-coated tablets
Each tablet contains 500 mg deferiprone.
Ferriprox 1000 mg film-coated tablets
Each tablet contains 1000 mg deferiprone.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet.
Ferriprox 500 mg film-coated tablets
White to off-white, capsule-shaped, film-coated tablets imprinted
“APO” bisect “500” on one side, plain
on the other. The tablet is scored. The tablet can be divided into
equal halves.
Ferriprox 1000 mg film-coated tablets
White to off-white, capsule-shaped, film-coated tablets imprinted
“APO” bisect “1000” on one side, plain
on the other. The tablet is scored. The tablet can be divided into
equal halves.
4. Clinical particulars
4.1 Therapeutic indications
Ferriprox monotherapy is indicated for the treatment of iron overload
in patients with thalassaemia major
when current chelation therapy is contraindicated or inadequate.
Ferriprox in combination with another chelator (see section 4.4) is
indicated in patients with thalassaemia
major when monotherapy with any iron chelator is ineffective, or when
prevention or treatment of life-
threatening consequences of iron overload (mainly cardiac overload)
justifies rapid or intensive correction
(see section 4.2).
4.2 Posology and method of administration
Deferiprone therapy should be initiated and maintained by a physician
experienced in the treatment of
patients with thalassaemia.
Posology
Deferiprone is usually given as 25 mg/kg body weight, orally, three
times a day for a total daily dose of
75 mg/kg body weight. Dose per kilogram body weight should be
calculated to the nearest half tablet. See
tables below for recommended doses for body weights at 10 kg
increments.
To obtain a dose of about